The initiation of Phase 2 expansion of the Darovasertib and Crizotinib combination by Ideaya Biosciences is a significant development for the company. This could potentially lead to a new treatment option for GNAQ/11 metastatic cutaneous melanoma, which would be a major breakthrough. This news is likely to have a positive impact on the company's stock in the short term as it indicates progress in their research and development efforts.